Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
Human respiratory syncytial virus (hRSV) infection is a leading cause of severe respiratory tract infections. Effective, directly acting antivirals against hRSV are not available. We aimed to discover new and chemically diverse candidates to enrich the hRSV drug development pipeline. We used a two-step screen that interrogates compound efficacy after primary infection and a consecutive virus passaging. We resynthesized selected hit molecules and profiled their activities with hRSV lentiviral pseudotype cell entry, replicon, and time-of-addition assays. The breadth of antiviral activity was tested against recent RSV clinical strains and human coronavirus (hCoV-229E), and in pseudotype-based entry assays with non-RSV viruses. Screening 6,048 molecules, we identified 23 primary candidates, of which 13 preferentially scored in the first and 10 in the second rounds of infection, respectively. Two of these molecules inhibited hRSV cell entry and selected for F protein resistance within the fusion peptide. One molecule inhibited transcription/replication in hRSV replicon assays, did not select for phenotypic hRSV resistance and was active against non-hRSV viruses, including hCoV-229E. One compound, identified in the second round of infection, did not measurably inhibit hRSV cell entry or replication/transcription. It selected for two coding mutations in the G protein and was highly active in differentiated BCi-NS1.1 lung cells. In conclusion, we identified four new hRSV inhibitor candidates with different modes of action. Our findings build an interesting platform for medicinal chemistry-guided derivatization approaches followed by deeper phenotypical characterization in vitro and in vivo with the aim of developing highly potent hRSV drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 66(2022), 12 vom: 20. Dez., Seite e0103222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sake, Svenja M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 22.12.2022 Date Revised 04.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/aac.01032-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348599943 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348599943 | ||
| 003 | DE-627 | ||
| 005 | 20231226040635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/aac.01032-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348599943 | ||
| 035 | |a (NLM)36346232 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sake, Svenja M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2022 | ||
| 500 | |a Date Revised 04.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Human respiratory syncytial virus (hRSV) infection is a leading cause of severe respiratory tract infections. Effective, directly acting antivirals against hRSV are not available. We aimed to discover new and chemically diverse candidates to enrich the hRSV drug development pipeline. We used a two-step screen that interrogates compound efficacy after primary infection and a consecutive virus passaging. We resynthesized selected hit molecules and profiled their activities with hRSV lentiviral pseudotype cell entry, replicon, and time-of-addition assays. The breadth of antiviral activity was tested against recent RSV clinical strains and human coronavirus (hCoV-229E), and in pseudotype-based entry assays with non-RSV viruses. Screening 6,048 molecules, we identified 23 primary candidates, of which 13 preferentially scored in the first and 10 in the second rounds of infection, respectively. Two of these molecules inhibited hRSV cell entry and selected for F protein resistance within the fusion peptide. One molecule inhibited transcription/replication in hRSV replicon assays, did not select for phenotypic hRSV resistance and was active against non-hRSV viruses, including hCoV-229E. One compound, identified in the second round of infection, did not measurably inhibit hRSV cell entry or replication/transcription. It selected for two coding mutations in the G protein and was highly active in differentiated BCi-NS1.1 lung cells. In conclusion, we identified four new hRSV inhibitor candidates with different modes of action. Our findings build an interesting platform for medicinal chemistry-guided derivatization approaches followed by deeper phenotypical characterization in vitro and in vivo with the aim of developing highly potent hRSV drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a RSV | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a drug screen | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Kosch, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Blockus, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Haid, Sibylle |e verfasserin |4 aut | |
| 700 | 1 | |a Gunesch, Antonia P |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Friesland, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Trummer, Sofie B |e verfasserin |4 aut | |
| 700 | 1 | |a Grethe, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Kühnel, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Rückert, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Duprex, W Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jiabin |e verfasserin |4 aut | |
| 700 | 1 | |a Rameix-Welti, Marie-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Empting, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Anna K H |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Thomas F |e verfasserin |4 aut | |
| 700 | 1 | |a Pietschmann, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 66(2022), 12 vom: 20. Dez., Seite e0103222 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2022 |g number:12 |g day:20 |g month:12 |g pages:e0103222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/aac.01032-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2022 |e 12 |b 20 |c 12 |h e0103222 | ||